NDA 022425 · Sanofi Aventis US
Multaq
Dronedarone Hydrochloride · Oral · Antiarrhythmic
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Oct 23, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 1, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
44
12 Phase 3, 4 recruiting
FAERS reports
10,242
7,225 serious, 673 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION In patients with symptomatic heart failure and recent decompensation requiring hospitalization or NYHA Class IV heart failure, MULTAQ doubles the risk of death [see Clinical Studies (14.3) ] . MULTAQ is contraindicated in patients with symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV heart failure [see Contraindications (4) , Warnings and Precautions (5.1) ] . In patients with permanent atrial fibrillation, MULTAQ doubles the risk of death, stroke and hospitalization for heart failure [see Clinical Studies (14.4) ] . MULTAQ is contraindicated in patients in atrial fibrillation (AF) who will not or cannot be cardioverted into normal sinus rhythm [see Contraindications (4) , Warnings and Precautions (5.2) ]...
What it is approved for
From the label in effect Jan 27, 2026.
MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ] . MULTAQ is an antiarrhythmic drug indicated to reduce the risk of hospitalization for atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF ( 1 , 14 ).
Mechanism: The mechanism of action of dronedarone is unknown. Dronedarone has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each of these activities to the clinical effect is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 23, 2023 Supplement 30 · Efficacy LetterLabelMedication Guide
- Jul 1, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelSummary ReviewReview
1 products under this application
- MULTAQ · DRONEDARONE HYDROCHLORIDE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dronedarone" as an intervention, any sponsor and status, largest first.
- A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial FibrillationPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00174785 · 4,628 participants · Start Jun 2005 · Primary completion Mar 2008
Drug: dronedarone (SR33589); placebo · For: Atrial Fibrillation; Atrial Flutter
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; New South Wales, Australia · 37 sites in all
- Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard TherapyPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT01151137 · 3,236 participants · Start Jul 2010 · Primary completion Sep 2011
Drug: Dronedarone; Placebo (for Dronedarone) · For: Atrial Fibrillation
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 37 sites in all
- Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesPivotal-lookingTerminated
Atrial Fibrillation NetworkAcademic, hospital or other
NCT02618577 · 2,608 participants · Start Feb 2016 · Primary completion Dec 31, 2022
Drug: Edoxaban; ASA · For: Atrial High Rate Episodes
Sites: Multiple Locations, Austria; Multiple Locations, Belgium; Multiple Locations, Bulgaria · 18 sites in all
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Dronedarone Rhythm Intervention for Early Atrial FibrillationPivotal-lookingNot yet recruiting
Inha University HospitalAcademic, hospital or other
NCT07270848 · 1,898 participants (planned) · Start Jan 1, 2026 · Primary completion Jun 2028
Drug: Dronedarone; flecainide and 1 more · For: Atrial Fibrillation (AF)
Sites: Incheon, South Korea; Ansan, South Korea; Bucheon-si, South Korea · 16 sites in all
- European Trial of Dronedarone in Moderate to Severe Congestive Heart FailurePivotal-lookingTerminated
SanofiSanofi (SNY)
NCT00696631 · 653 participants · Start Jun 2002 · Primary completion Jan 2003
Drug: Dronedarone (SR33589); Placebo · For: Congestive Heart Failure
Sites: Hørsholm, Denmark; Budapest, Hungary; Gouda, Netherlands · 6 sites in all
- American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus RhythmPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00259376 · 629 participants · Start Nov 2001 · Primary completion Sep 2003
Drug: Dronedarone (SR33589); placebo · For: Atrial Fibrillation; Atrial Flutter
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Macquarie Park, Australia · 5 sites in all
- EURopean Trial In Atrial Fibrillation(AF) or Flutter (AFL) Patients Receiving Dronedarone for the maIntenance of Sinus Rhythm (EURIDIS)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00259428 · 615 participants · Start Nov 2001 · Primary completion Aug 2003
Drug: Dronedarone (SR33589); placebo · For: Atrial Fibrillation; Atrial Flutter
Sites: Diegem, Belgium; Prague, Czechia; Hørsholm, Denmark · 12 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial fibrillation1,428
- dyspnoea850
- fatigue627
- off label use571
- diarrhoea487
- nausea479
- drug interaction471
- dizziness454
- gastrointestinal haemorrhage421
- asthenia385
- drug ineffective337
- blood creatinine increased311
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 200 |
| 2010 | 1,088 |
| 2011 | 1,499 |
| 2012 | 632 |
| 2013 | 789 |
| 2014 | 747 |
| 2015 | 787 |
| 2016 | 645 |
| 2017 | 483 |
| 2018 | 471 |
| 2019 | 501 |
| 2020 | 405 |
| 2021 | 318 |
| 2022 | 302 |
| 2023 | 294 |
| 2024 | 327 |
| 2025 | 413 |
| 2026 | 341 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Multaq (Dronedarone HCl)
2024 spending
$415M
Beneficiaries
72,761
318,776 claims
Per beneficiary
$5,700
$12.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $342,150,558 |
| 2021 | $356,717,638 |
| 2022 | $386,678,239 |
| 2023 | $409,348,468 |
| 2024 | $414,751,255 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Dronedarone in Overweight and Obesity: Post Hoc Analysis of the ATHENA Trial.
Vamos M, Vagvolgyi A, McKindley DS, et al. · J Cardiovasc Electrophysiol 2026 · Randomized Controlled Trial, Multicenter Study
- Dronedarone in patients with congestive heart failure: insights from ATHENA.
Hohnloser SH, Crijns HJ, van Eickels M, et al. · Eur Heart J 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Post-ATHENA and beyond.
Naccarelli GV · J Interv Card Electrophysiol 2011 · Controlled Clinical Trial
- Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study.
Blomström-Lundqvist C, Marrouche N, Connolly S, et al. · Clin Cardiol 2020 · Clinical Trial, Phase III, Multicenter Study
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Cost-effectiveness of dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland.
Åkerborg Ö, Nilsson J, Bascle S, et al. · Clin Ther 2012 · Clinical Trial, Multicenter Study
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.